Dr Reddy’s Laboratories has acquired the anti-vertigo brand Stugeron from Johnson & Johnson in 18 EMEA and APAC markets, including India and Vietnam. The move strengthens its CNS portfolio and supports its goal to reach 1.5 billion patients by 2030
The company has also offered voluntary retirement to employees aged 50-55 within its research and development division; multiple high-salaried employees across various departments have already been asked to resign, reports stated
The drug is the only immuno-oncology drug approved by various regulatory authorities around the world for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), an aggressive form of head and neck cancer that originates in the upper part of the throat
D. Sai Prasad, Chairman, CII Telangana & Executive Director, Bharat Biotech International, underscored the importance of the CII CFO Forum as a platform for finance professionals to exchange strategies and insights.
